None listed
Conditions
Interventions
Drug : The primary assessment criteria will be the change between baseline and after minirin® administration in sleep pattern and voiding pattern during 10 days of work shift duty. Orally ingest minir
Sponsors
Ferring pharmaceuticals Korea
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Female nurse at the age of 20 ~ 50 who assigned to the general ward and sifted to the nigh duty 2) A woman without any LUTS 3) A woman who has given written informed consent from voluntarily before any trial related actives
Exclusion criteria
Exclusion criteria: 1) A woman who has history of urinary tract infections within one month. 2) A woman who has been treated with alpha-blocker, anticholinergic, cholinergic, diuretic for more than three months. 3) A woman who is during her menstrual period 4) A woman who is pregnant or is under breast feeding 5) A woman who has history of SIADH 6) A woman who has nocturnal polyuria, hypertention, chronic renal disease, or cardiovascular disease 7) A woman who has habitual or psychotic polydypsia (24 hrs urine output > 40ml/kg) 8) A woman who has history of chronic pelvic pain syndrome. 9) A woman who has history of cancer in abdominal or endopelvis. 10) A woman who treated with pelvic radiation therapy. 11) A woman who received transurethral resection (TUR). 12) A woman diagnosed with interstitial cystitis. 13) A woman who be considered unacceptable by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| voiding diary ;OABSS: overactive bladder symptom score;PSQI-K: Pittsburgh Sleep Quality Index Korean;KESS: Korean version of the Epworth Sleepiness Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| BSW ( Benefit, satisfaction, willingness) ;Initial sleep time/ Total sleep time | — |
Countries
Korea, Republic of
Contacts
Public ContactKyung Jin Chung
Gachon University Gil Medical Center
Outcome results
None listed